

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2024

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 000-52566

**SUMMIT HEALTHCARE REIT, INC.**

(Exact name of registrant as specified in its charter)

MARYLAND  
(State or other jurisdiction of  
incorporation or organization)

73-1721791  
(I.R.S. Employer  
Identification No.)

23382 MILL CREEK DRIVE, SUITE 125,  
LAGUNA HILLS, CA  
(Address of principal executive offices)

92653  
(Zip Code)

800-978-8136  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Ticker symbol(s)	Name of each exchange on which registered
N/A	N/A	N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Sec. 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes  No

As of November 4, 2024, we had 23,027,978 shares of common stock of Summit Healthcare REIT, Inc. outstanding.

FORM 10-Q

SUMMIT HEALTHCARE REIT, INC. AND SUBSIDIARIES  
TABLE OF CONTENTS

<b><u>PART I. FINANCIAL INFORMATION</u></b>	
<u>Item 1. Financial Statements:</u>	3
<u>Condensed Consolidated Balance Sheets (unaudited)</u>	3
<u>Condensed Consolidated Statements of Operations (unaudited)</u>	4
<u>Condensed Consolidated Statements of Equity (Deficit) (unaudited)</u>	5
<u>Condensed Consolidated Statements of Cash Flows (unaudited)</u>	6
<u>Notes to Condensed Consolidated Financial Statements (unaudited)</u>	7
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	22
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	30
<u>Item 4. Controls and Procedures</u>	30
<b><u>PART II. OTHER INFORMATION</u></b>	
<u>Item 1. Legal Proceedings</u>	31
<u>Item 1A. Risk Factors</u>	31
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	31
<u>Item 3. Defaults Upon Senior Securities</u>	31
<u>Item 4. Mine Safety Disclosures</u>	31
<u>Item 5. Other Information</u>	31
<u>Item 6. Exhibits</u>	32
<u>SIGNATURES</u>	33
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32</u>	

**PART I — FINANCIAL INFORMATION**

**Item 1. Financial Statements.**

**SUMMIT HEALTHCARE REIT, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)**

	September 30, 2024	December 31, 2023
<b>ASSETS</b>		
Cash and cash equivalents	\$ 24,198,000	\$ 10,997,000
Restricted cash	2,873,000	3,186,000
Real estate properties, net (Note 14)	40,270,000	156,966,000
Intangible lease assets, net (Notes 8 and 14)	—	11,653,000
Tenant and other receivables, net	1,811,000	2,590,000
Other assets, net	1,160,000	1,552,000
Equity-method investments	415,000	2,852,000
Contract assets associated with GA8 Properties (Note 14)	130,880,000	—
Total assets	<u>\$ 201,607,000</u>	<u>\$ 189,796,000</u>
<b>LIABILITIES AND EQUITY (DEFICIT)</b>		
Accounts payable and accrued liabilities	\$ 4,368,000	\$ 7,038,000
Accrued interest associated with GA8 Properties (Note 14)	8,540,000	1,041,000
Security deposits (Note 14)	338,000	3,705,000
Loans payable, net of debt issuance costs	41,315,000	56,179,000
Loans payable associated with GA8 Properties (Note 14)	122,340,000	123,750,000
Total liabilities	<u>176,901,000</u>	<u>191,713,000</u>
Commitments and contingencies		
Stockholders' Equity (Deficit)		
Preferred stock, \$0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding at September 30, 2024 and December 31, 2023	—	—
Common stock, \$0.001 par value; 290,000,000 shares authorized; 23,027,978 shares issued and outstanding at September 30, 2024 and December 31, 2023	23,000	23,000
Additional paid-in capital	116,509,000	116,473,000
Accumulated deficit	(91,972,000)	(118,535,000)
Total stockholders' equity (deficit)	<u>24,560,000</u>	<u>(2,039,000)</u>
Noncontrolling interests	146,000	122,000
Total equity (deficit)	<u>24,706,000</u>	<u>(1,917,000)</u>
Total liabilities and equity	<u>\$ 201,607,000</u>	<u>\$ 189,796,000</u>

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

**SUMMIT HEALTHCARE REIT, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)**

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
<b>Revenues:</b>				
Total rental revenues	\$ 1,718,000	\$ 4,552,000	\$ 7,648,000	\$ 15,298,000
Resident fees and services	1,788,000	2,084,000	5,217,000	5,086,000
Asset management fees	55,000	129,000	219,000	423,000
<b>Total operating revenue</b>	<b>3,561,000</b>	<b>6,765,000</b>	<b>13,084,000</b>	<b>20,807,000</b>
<b>Expenses:</b>				
Property operating costs	210,000	917,000	1,164,000	2,469,000
Resident costs	1,601,000	2,095,000	4,458,000	4,362,000
General and administrative	986,000	1,403,000	3,360,000	3,598,000
Depreciation and amortization	408,000	2,066,000	2,358,000	5,685,000
Impairment of real estate properties	—	11,387,000	—	11,387,000
<b>Total operating expenses</b>	<b>3,205,000</b>	<b>17,868,000</b>	<b>11,340,000</b>	<b>27,501,000</b>
Gain on derecognition associated with GA8 Properties	(6,434,000)	—	(27,455,000)	—
Gain on sale of real estate properties (Note 3)	(11,151,000)	—	(11,151,000)	—
<b>Operating income (loss)</b>	<b>17,941,000</b>	<b>(11,103,000)</b>	<b>40,350,000</b>	<b>(6,694,000)</b>
(Loss) income from equity-method investees	(69,000)	(1,671,000)	1,797,000	(1,429,000)
Other income	148,000	103,000	349,000	299,000
Interest expense	(744,000)	(1,129,000)	(2,617,000)	(3,204,000)
Interest expense associated with GA8 Properties	(6,434,000)	(3,413,000)	(13,233,000)	(9,806,000)
Gain on consolidation of interest in unconsolidated equity-method investment	—	1,066,000	—	1,066,000
<b>Net income (loss)</b>	<b>10,842,000</b>	<b>(16,147,000)</b>	<b>26,646,000</b>	<b>(19,768,000)</b>
Noncontrolling interests' share in net (income) loss	(36,000)	38,000	(83,000)	2,000
<b>Net income (loss) applicable to common stockholders</b>	<b>\$ 10,806,000</b>	<b>\$ (16,109,000)</b>	<b>\$ 26,563,000</b>	<b>\$ (19,766,000)</b>
<b>Basic and diluted:</b>				
Net income (loss) applicable to common stockholders	\$ 0.47	\$ (0.70)	\$ 1.15	\$ (0.86)
Weighted average shares used to calculate basic and diluted earnings per common share	23,027,978	23,027,978	23,027,978	23,027,978

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

**SUMMIT HEALTHCARE REIT, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (DEFICIT)**  
**(Unaudited)**

	Common Stock			Accumulated Deficit	Total Stockholders' Equity (Deficit)	Noncontrolling Interests	Total Equity (Deficit)
	Number of Shares	Common Stock Par Value	Additional Paid-In Capital				
<b>Balance — January 1, 2024</b>	23,027,978	\$ 23,000	\$ 116,473,000	\$ (118,535,000)	\$ (2,039,000)	\$ 122,000	\$ (1,917,000)
Stock-based compensation	—	—	12,000	—	12,000	—	12,000
Distributions paid to noncontrolling interests	—	—	—	—	—	(18,000)	(18,000)
Net income	—	—	—	15,303,000	15,303,000	22,000	15,325,000
<b>Balance — March 31, 2024</b>	23,027,978	\$ 23,000	\$ 116,485,000	\$ (103,232,000)	\$ 13,276,000	\$ 126,000	\$ 13,402,000
Stock-based compensation	—	—	12,000	—	12,000	—	12,000
Distributions paid to noncontrolling interests	—	—	—	—	—	(19,000)	(19,000)
Net income	—	—	—	454,000	454,000	25,000	479,000
<b>Balance — June 30, 2024</b>	23,027,978	\$ 23,000	\$ 116,497,000	\$ (102,778,000)	\$ 13,742,000	\$ 132,000	\$ 13,874,000
Stock-based compensation	—	—	12,000	—	12,000	—	12,000
Distributions paid to noncontrolling interests	—	—	—	—	—	(22,000)	(22,000)
Net income	—	—	—	10,806,000	10,806,000	36,000	10,842,000
<b>Balance — September 30, 2024</b>	23,027,978	\$ 23,000	\$ 116,509,000	\$ (91,972,000)	\$ 24,560,000	\$ 146,000	\$ 24,706,000

	Common Stock			Accumulated Deficit	Total Stockholders' Equity	Noncontrolling Interests	Total Equity
	Number of Shares	Common Stock Par Value	Additional Paid-In Capital				
<b>Balance — January 1, 2023</b>	23,027,978	\$ 23,000	\$ 116,432,000	\$ (93,734,000)	\$ 22,721,000	\$ 177,000	\$ 22,898,000
Stock-based compensation	—	—	7,000	—	7,000	—	7,000
Distributions paid to noncontrolling interests	—	—	—	—	—	(17,000)	(17,000)
Net (loss) income	—	—	—	(1,976,000)	(1,976,000)	17,000	(1,959,000)
<b>Balance — March 31, 2023</b>	23,027,978	\$ 23,000	\$ 116,439,000	\$ (95,710,000)	\$ 20,752,000	\$ 177,000	\$ 20,929,000
Stock-based compensation	—	—	10,000	—	10,000	—	10,000
Distributions paid to noncontrolling interests	—	—	—	—	—	(19,000)	(19,000)
Net (loss) income	—	—	—	(1,681,000)	(1,681,000)	19,000	(1,662,000)
<b>Balance — June 30, 2023</b>	23,027,978	\$ 23,000	\$ 116,449,000	\$ (97,391,000)	\$ 19,081,000	\$ 177,000	\$ 19,258,000
Stock-based compensation	—	—	12,000	—	12,000	—	12,000
Distributions paid to noncontrolling interests	—	—	—	—	—	(20,000)	(20,000)
Net (loss) income	—	—	—	(16,109,000)	(16,109,000)	(38,000)	(16,147,000)
<b>Balance — September 30, 2023</b>	23,027,978	\$ 23,000	\$ 116,461,000	\$ (113,500,000)	\$ 2,984,000	\$ 119,000	\$ 3,103,000

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

**SUMMIT HEALTHCARE REIT, INC. AND SUBSIDIARIES**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited)

	Nine months Ended September 30,	
	2024	2023
<b>Cash flows from operating activities:</b>		
Net income (loss)	\$ 26,646,000	\$ (19,768,000)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:		
Amortization of debt issuance costs	241,000	685,000
Depreciation and amortization	2,358,000	5,430,000
Amortization of above-market lease intangible	42,000	48,000
Straight-line rents	(173,000)	(920,000)
Write off of straight-line rent receivables	—	1,300,000
Stock-based compensation expense	36,000	29,000
Write-off of leasing commissions	—	255,000
Impairment of real estate properties	—	11,387,000
Gain on consolidation of interest in unconsolidated equity-method investment	—	(1,066,000)
Gain on sale of real estate properties	(11,151,000)	—
Gain on derecognition of assets associated with GA8 Properties	(27,455,000)	—
(Income) loss from equity-method investees	(1,797,000)	1,429,000
Change in operating assets and liabilities, net of derecognition of assets:		
Tenant and other receivables, net	2,046,000	45,000
Other assets, net	307,000	232,000
Accounts payable and accrued liabilities	7,053,000	1,148,000
Security deposits	(109,000)	(420,000)
<b>Net cash used in operating activities</b>	<b>(1,956,000)</b>	<b>(186,000)</b>
<b>Cash flows from investing activities:</b>		
Proceeds from sale of real estate properties assigned	—	3,839,000
Cash assumed in assignment of interest in unconsolidated equity-method investment	—	770,000
Proceeds from sale of real estate properties, net of cash	27,906,000	—
Change in cash associated with the derecognition of assets associated with GA8 Properties	1,924,000	—
Additions to real estate and other assets	(258,000)	(243,000)
Investment in equity-method investees	(29,000)	(230,000)
Distributions received from equity-method investees	2,665,000	550,000
<b>Net cash provided by investing activities</b>	<b>32,208,000</b>	<b>4,686,000</b>
<b>Cash flows from financing activities:</b>		
Payments of loans payable	(2,305,000)	(862,000)
Repayment of loan payable assigned	—	(3,171,000)
Repayment of loan payable related to sale of real estate properties	(15,000,000)	—
Distributions paid to noncontrolling interests	(59,000)	(56,000)
Deferred financing costs	—	(86,000)
<b>Net cash used in financing activities</b>	<b>(17,364,000)</b>	<b>(4,175,000)</b>
Net increase in cash, cash equivalents and restricted cash	12,888,000	325,000
Cash, cash equivalents and restricted cash – beginning of period	14,183,000	14,163,000
Cash, cash equivalents and restricted cash – end of period	<b>\$ 27,071,000</b>	<b>\$ 14,488,000</b>
<b>Supplemental disclosure of cash flow information:</b>		
Cash paid for interest	\$ 8,514,000	\$ 12,007,000
<b>Supplemental disclosure of non-cash financing and investing activities:</b>		
Consolidation of assets, net, in connection with our acquisition of partner's interest in unconsolidated equity-method investment	—	313,000
<b>Derecognition of assets associated with GA8 Properties (Note 14):</b>		
Real estate properties, net	\$ 97,637,000	\$ —
Intangible lease assets, net	\$ 10,250,000	\$ —
Other assets	\$ 12,000	\$ —
Accounts payable and accrued liabilities	\$ (821,000)	\$ —
Write off of deferred financing costs	\$ 790,000	\$ —
Security deposits	\$ (2,589,000)	\$ —

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

**SUMMIT HEALTHCARE REIT, INC. AND SUBSIDIARIES**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**SEPTEMBER 30, 2024**  
**(Unaudited)**

**1. Organization**

Summit Healthcare REIT, Inc. (“Summit”) is a real estate investment trust that, as of September 30, 2024, owns 100% of 11 properties (eight of which were derecognized in March 2024 and are included in contract assets associated with GA8 Properties (see Note 14)), 95.3% of four properties, and three unconsolidated equity-method investments with interests ranging from 10% - 20% that hold an aggregate of 21 properties. As used in these notes, the “Company”, “we”, “us” and “our” refer to Summit and its consolidated subsidiaries, including but not limited to Summit Healthcare Operating Partnership, L.P. (the “Operating Partnership”), except where the context otherwise requires.

We conduct substantially all of our operations through the Operating Partnership, which is a Delaware limited partnership. We own a 99.88% general partner interest in the Operating Partnership, and Cornerstone Realty Advisors, LLC (“CRA”), a former affiliate, owns a 0.12% limited partnership interest.

Summit and the Operating Partnership are managed and operated as one entity, and Summit has no significant assets other than its investment in the Operating Partnership. Summit, as the general partner of the Operating Partnership, controls the Operating Partnership and consolidates the assets, liabilities, and results of operations of the Operating Partnership.

***Cornerstone Healthcare Partners LLC – Consolidated Joint Venture***

We own 95% of Cornerstone Healthcare Partners LLC (“CHP LLC”), which was formed in 2012, and the remaining 5% noncontrolling interest is owned by Cornerstone Healthcare Real Estate Fund, Inc. (“CHREF”), an affiliate of CRA. CHP LLC is consolidated within our condensed consolidated financial statements and owns four properties (the “JV Properties”) with another partially owned subsidiary. As of September 30, 2024 and December 31, 2023, we own a 95.3% interest in the four JV Properties, and CHREF owns a 4.7% interest.

***Summit Union Life Holdings, LLC – Equity-Method Investment***

In April 2015, through our Operating Partnership, we entered into a limited liability company agreement with Best Years, LLC (“Best Years”), an unrelated entity and a U.S.-based affiliate of Union Life Insurance Co, Ltd. (a Chinese corporation), and formed Summit Union Life Holdings, LLC (the “SUL JV”). The SUL JV is not consolidated in our condensed consolidated financial statements and is accounted for under the equity-method in our condensed consolidated financial statements. As of September 30, 2024, we have a 10% interest in the SUL JV which owns 13 properties as of September 30, 2024 and as of December 31, 2023, owned 15 properties.

***Summit Fantasia Holdings II, LLC – Equity-Method Investment***

In December 2016, through our Operating Partnership, we entered into a limited liability company agreement with Fantasia, and formed Summit Fantasia Holdings II, LLC (the “Fantasia II JV”). The Fantasia II JV is not consolidated in our condensed consolidated financial statements and is accounted for under the equity-method in our condensed consolidated financial statements. As of September 30, 2024 and December 31, 2023, we have a 20% interest in the Fantasia II JV which owns two properties.

***Summit Fantasia Holdings III, LLC – Equity-Method Investment***

In July 2017, through our Operating Partnership, we entered into a limited liability company agreement with Fantasia and formed Summit Fantasia Holdings III, LLC (the “Fantasia III JV”). The Fantasia III JV was not consolidated in our condensed consolidated financial statements and was accounted for under the equity-method in our condensed consolidated financial statements. As of December 31, 2023, we had a 10% interest in the Fantasia III JV which owned eight properties.

In May 2024, the Fantasia III JV sold their eight properties for \$60.0 million. We received approximately \$2.1 million in cash from the sale resulting in the winding-up of our equity-method investment and as such, as of May 2, 2024, we no longer have an equity-method investment in the Fantasia III JV.

***Summit Fantasy Pearl Holdings, LLC – Equity-Method Investment***

In October 2017, through our Operating Partnership, we entered into a limited liability company agreement with Fantasia, Atlantis Senior Living 9, LLC, a Delaware limited liability company (“Atlantis”), and Fantasy Pearl LLC, a Delaware limited liability company (“Fantasy”), and formed Summit Fantasy Pearl Holdings, LLC (the “FPH JV”). The FPH JV is not consolidated in our condensed consolidated financial statements and is accounted for under the equity-method in our condensed consolidated financial statements. As of September 30, 2024 and December 31, 2023, we have a 10% interest in the FPH JV which owns six properties.

***Taxable REIT Subsidiaries***

**Summit Healthcare Asset Management, LLC**

Summit Healthcare Asset Management, LLC (“SAM TRS”) is our wholly-owned taxable REIT subsidiary (“TRS”). We serve as the manager of the SUL JV, Fantasia I JV (through July 2, 2023), Fantasia II JV, Fantasia III JV (through May 2, 2024), and FPH JV (collectively, our “Equity-Method Investments”), and provide management services in exchange for fees and reimbursements. All asset management fees earned by us are paid to SAM TRS and expenses incurred by us, as the manager, are reimbursed from SAM TRS. See Notes 5 and 7 for further information.

**SHOP TRS LLC**

SHOP TRS LLC (“SHOP TRS”) is our wholly-owned taxable REIT subsidiary that is the sole member for two of our operated properties which are the lessees for our two respective 100% owned real estate properties and the operated properties operations are consolidated in our condensed consolidated financial statements.

**2. Summary of Significant Accounting Policies**

For more information regarding our significant accounting policies and estimates, please refer to “Summary of Significant Accounting Policies” contained in the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (“SEC”) on April 16, 2024. The accompanying condensed consolidated balance sheet at December 31, 2023 has been derived from the audited consolidated financial statements at that date. We assume that users of these condensed consolidated financial statements have read or have access to the audited December 31, 2023 consolidated financial statements and contained in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 16, 2024 and that the adequacy of additional disclosure needed for a fair presentation, except in regard to material contingencies, may be determined in that context. Accordingly, footnotes and other disclosures which would substantially duplicate those contained in our most recent Annual Report on Form 10-K for the year ended December 31, 2023 have been omitted in this report.

***Principles of Consolidation and Basis of Presentation***

The accompanying condensed consolidated financial statements include the accounts of the Company, its wholly-owned subsidiaries, the Operating Partnership and its consolidated companies and are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). All intercompany accounts and transactions have been eliminated in consolidation.

The accompanying financial information reflects all adjustments, which are, in the opinion of management, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year. Operating results for the three and nine months ended September 30, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024.

***Reclassifications***

Certain line items on the December 31, 2023 condensed consolidated balance sheet for loans payable and accounts payable and accrued liabilities and on the condensed consolidated statement of operations for interest expense for the three and nine months ended September 30, 2023 have been reclassified to conform to the current period presentation. See Note 14.



[Table of Contents](#)**Restricted Cash**

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheets that sum to the total of the same such amounts shown on the condensed consolidated statements of cash flows.

	September 30, 2024	December 31, 2023
Cash and cash equivalents	\$ 24,198,000	\$ 10,997,000
Restricted cash	2,873,000	3,186,000
Total cash, cash equivalents, and restricted cash shown on the condensed consolidated statements of cash flows	<u>\$ 27,071,000</u>	<u>\$ 14,183,000</u>

**Recent Accounting Pronouncements**

In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures." This ASU enhances reportable segment disclosures on both an annual and interim basis primarily in regard to the disclosure of significant segment expenses that are regularly provided to the chief operating decision maker (CODM) and included within the reported measure(s) of segment profit or loss. In addition, the ASU requires disclosure, by segment, of other items included in the reported measure(s) of segment profit or loss, including qualitative information describing the composition, nature and type of each item. The ASU also expands disclosure requirements related to the CODM, including how the reported measure(s) of segment profit or loss are used to assess segment performance and allocate resources, the method used to allocate overhead for significant segment expenses and others. Lastly, all previously required annual segment reporting disclosures under Topic 280 will also be required for interim periods. The ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is evaluating the impact of adopting this ASU.

In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Topic 220): Disaggregation of Income Statement Expenses. This guidance requires additional disclosure of certain amounts included in the expense captions presented on the Statement of Operations as well as disclosures about selling expenses. The ASU is effective on a prospective basis, with the option for retrospective application, for annual periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted for annual financial statements that have not yet been issued. The Company is evaluating the impact of adopting this ASU.

**3. Investments in Real Estate Properties**

The table below includes, as of September 30, 2024, seven real estate properties held by our consolidated subsidiaries, five of which are 100% leased to the tenants of the related facilities and two are each 100% leased to an affiliated subsidiary. The table below includes, as of December 31, 2023, ten real estate properties held by our consolidated subsidiaries, eight of which were 100% leased to the tenants of the related facilities and two were each 100% leased to an affiliated subsidiary. As of September 30, 2024, the table below excludes our eight derecognized real estate properties (see Note 14) and as of September 30, 2024 and December 31, 2023, excludes the 21 and 31 properties, respectively, owned by our unconsolidated Equity-Method Investments.

	September 30, 2024	December 31, 2023
Land	\$ 6,237,000	\$ 14,905,000
Buildings and improvements	48,628,000	157,875,000
Less: accumulated depreciation	(14,767,000)	(20,439,000)
Buildings and improvements, net	33,861,000	137,436,000
Furniture and fixtures	4,534,000	12,106,000
Less: accumulated depreciation	(4,362,000)	(7,481,000)
Furniture and fixtures, net	172,000	4,625,000
Real estate properties, net	<u>\$ 40,270,000</u>	<u>\$ 156,966,000</u>

For the three months ended September 30, 2024 and 2023, depreciation expense (excluding lease intangibles amortization and leasing commission amortization) was approximately \$0.4 million and \$1.6 million, respectively. For the nine months ended September 30,

[Table of Contents](#)

2024 and 2023, depreciation expense (excluding intangible lease amortization and leasing commission amortization) was approximately \$2.2 million and \$4.7 million, respectively.

**Sale of CA3 Properties**

In 2021, we acquired three properties located in California (“CA3 Properties”) and we entered into a first priority \$15.0 million mortgage loan collateralized by the CA3 Properties with CIBC Bank, USA (“CIBC”). On September 6, 2024, we completed the sale of the CA3 Properties for an aggregate sales price of \$30.0 million. The net cash proceeds we received following the closing of the CA3 Properties was approximately \$14.9 million after the payoff of the outstanding \$15.0 million loan payable from CIBC Bank, USA, and less the expenses and fees incurred with the sale. We recorded a gain on the sale of approximately \$11.2 million, which is recorded in gain on sale of real estate properties in the condensed consolidated statements of operations.

**Fantasia I JV Transfer of Interest and Sale**

On July 3, 2023, the majority member of the Fantasia I JV assigned its 65% interest, for no consideration, to Summit. As such, as of July 2023, Summit owned 100% of Fantasia I JV. The Fantasia I JV consisted of the real estate of Summit Citrus Heights, LLC, a wholly-owned subsidiary (“Summit Citrus Heights”) and the operating assets and liabilities of its associated senior housing facility, Sun Oak Assisted Living (“Sun Oak” or “CH TRS”). Summit Citrus Heights was the sole member of CH TRS LLC, the operating company for Sun Oak. On September 29, 2023, we sold the real estate of Summit Citrus Heights, including the Sun Oak facility.

**Summary of Properties**

The following table provides summary information regarding our portfolio (excluding the 21 properties owned by our unconsolidated Equity-Method Investments, and our 8 derecognized real estate properties (see Note 14)) as of September 30, 2024:

Property	Location	Date Purchased	Type <sup>(1)</sup>	Purchase Price	Loans Payable, Excluding Debt Issuance Costs
Rivers Edge Rehabilitation and Care (f/k/a Sheridan Care Center)	Sheridan, OR	August 3, 2012	SNF	\$ 4,100,000	\$ 3,695,000
Fernhill Care Center	Portland, OR	August 3, 2012	SNF	4,500,000	3,241,000
Friendship Haven Healthcare and Rehabilitation Center	Galveston County, TX	September 14, 2012	SNF	15,000,000	10,942,000
Pacific Health and Rehabilitation Center	Tigard, OR	December 24, 2012	SNF	8,140,000	5,402,000
Brookstone of Aledo	Aledo, IL	July 2, 2013	AL	8,625,000	6,354,000
Sundial Assisted Living	Redding, CA	December 18, 2013	AL	3,500,000	3,581,000
Pennington Gardens	Chandler, AZ	July 17, 2017	AL/MC	13,400,000	9,751,000
Total:				<u>\$ 57,265,000</u>	<u>\$ 42,966,000</u>

(1) SNF is an abbreviation for skilled nursing facility.

AL is an abbreviation for assisted living facility.

MC is an abbreviation for memory care facility.

**Future Minimum Lease Payments**

The future minimum lease payments to be received under our existing tenant operating leases (excluding the 21 properties owned by our unconsolidated Equity-Method Investments, our eight derecognized subsidiaries (see Note 14), and the two intercompany leases between our wholly-owned subsidiaries: Summit Chandler LLC and Pennington Gardens, and HP Redding LLC and Sundial) as of September 30, 2024, for the period from October 1, 2024 to December 31, 2024 and for each of the four following years and thereafter ending December 31 are as follows:

[Table of Contents](#)

Years ending	
October 1, 2024 to December 31, 2024	\$ 1,092,000
2025	4,437,000
2026	4,525,000
2027	4,616,000
2028	3,140,000
Thereafter	12,775,000
	<u>\$ 30,585,000</u>

**Impairment of Real Estate Properties**

As a result of our ongoing analysis for potential impairment of our investments in real estate, we may be required to adjust the carrying value of certain assets to their estimated fair values, or estimated fair value less selling costs, under certain circumstances.

No impairments were recorded during the three and nine months ended September 30, 2024.

During the three and nine months ended September 30, 2023, we recorded an impairment of approximately \$11.4 million related to eight real estate properties, which is included in impairment of real estate properties in the condensed consolidated statements of operations. The impairment was recorded due to the tenants experiencing issues affecting their ability to continue to pay their lease obligations. We utilized a market approach for the fair value estimate of the real estate properties and based our impairment on an estimated yield of 10.8%. We considered these inputs as Level 3 measurements within the fair value hierarchy.

**4. Loans Payable**

As of September 30, 2024 and December 31, 2023, our loans payable consisted of the following:

	September 30, 2024	December 31, 2023
Loans payable to Lument (formerly ORIX Real Estate Capital, LLC) (insured by HUD) in monthly installments of approximately \$183,000, including interest, ranging from a fixed rate of 2.79% to 4.2%, due in September 2039 through April 2055, and collateralized by Sheridan, Fernhill, Pacific Health, Aledo, Sundial and Friendship Haven.	\$ 33,215,000	\$ 33,984,000
Loan payable to Capital One Multifamily Finance, LLC (insured by HUD) in monthly installments of approximately \$49,000, including interest at a fixed rate of 4.23%, due in September 2053, and collateralized by Pennington Gardens.	9,751,000	9,877,000
Loan payable to CIBC Bank, USA was in monthly installments of approximately of \$147,000 including cash collateral fund payments, variable interest rate (9.4% at December 31, 2023), and, collateralized by Yucaipa Hill Post Acute, Creekside Post Acute and University Post Acute ("CA3 Properties"). See Note 3 for additional information regarding the sale of these properties on September 6, 2024.	—	15,000,000
	<b>42,966,000</b>	<b>58,861,000</b>
<b>Less debt issuance costs</b>	<b>(1,651,000)</b>	<b>(2,682,000)</b>
<b>Total loans payable</b>	<b>\$ 41,315,000</b>	<b>\$ 56,179,000</b>

As of September 30, 2024, we have total debt obligations of approximately \$43.0 million that will mature between 2039 and 2055, in addition to the loans payable associated with GA8 Properties discussed below. See Note 3 for loans payable balance for each property. All of the loans payable have certain financial and non-financial covenants, including ratios and financial statement considerations. As of September 30, 2024, we were in compliance with all of our debt covenants except for the GA8 Properties (see below and Note 14 for further information).

During the three months ended September 30, 2024 and 2023, we incurred approximately \$7.2 million and \$4.3 million of interest expense, respectively, including interest expense related to the GA8 Properties (see below for further information) and excluding debt issuance costs and amortization. During the nine months ended September 30, 2024 and 2023, we incurred approximately \$15.9 million

[Table of Contents](#)

and \$12.3 million of interest expense, respectively, including interest expense related to the GA8 Properties and excluding debt issuance costs and amortization.

In connection with our loans payable, we incurred debt issuance costs. As of September 30, 2024 and December 31, 2023, the unamortized balance of the debt issuance costs was approximately \$1.7 million and \$2.7 million, respectively. These debt issuance costs are being amortized over the life of their respective financing agreements using the straight-line basis which approximates the effective interest rate method. For the three months ended September 30, 2024 and 2023, \$0.02 million and \$0.2 million, respectively of debt issuance costs were amortized and included in interest expense in our condensed consolidated statements of operations. For the nine months ended September 30, 2024 and 2023, \$0.2 million and \$0.7 million, respectively of debt issuance costs were amortized and included in interest expense in our condensed consolidated statements of operations.

The principal payments due on the loans payable (excluding debt issuance costs and loans payable associated with GA8 Properties) for the period from October 1, 2024 to December 31, 2024 and for each of the four following years and thereafter ending December 31 are as follows:

<b>Years Ending</b>	<b>Principal Amount</b>
October 1, 2024 to December 31, 2024	\$ 304,000
2025	1,246,000
2026	1,292,000
2027	1,341,000
2028	1,390,000
Thereafter	37,393,000
	<u>\$ 42,966,000</u>

**GA8 Properties**

In 2021, through our wholly-owned subsidiary and the parent holding company for the GA8 Properties, Summit Georgia Holdings LLC (“GA Holdco”), we acquired eight skilled nursing facilities located in Georgia (collectively, the “GA8 Properties”). The GA8 Properties were financed with a \$91.0 million first priority mortgage loan with CIBC collateralized by those properties, a \$20.0 million subordinated term loan with Oxford Finance LLC (“Oxford”) collateralized by those properties and a \$12.75 million mezzanine loan with Oxford secured by the equity interests of the GA Holdco.

During 2023 and 2024, we have been out of compliance with respect to our debt covenants for our GA8 Properties due to the tenants’ EBITDAR (earnings before interest, taxes, depreciation, amortization and rent) default and from our continuing failure to pay the full and timely interest payments due on the mezzanine loan since October 2023, and for the subordinated term loan since January 2024. Oxford had previously agreed to defer a portion of our interest payments on the mezzanine loan for October and November 2023. As of September 30, 2024 and December 31, 2023, the outstanding interest due on the mezzanine loan is approximately \$3.4 million and \$0.6 million, respectively, which, as of September 30, 2024, includes default interest of 5% of approximately \$1.2 million that was assessed by the lender in September 2024. As of September 30, 2024 and December 31, 2023, the outstanding interest due on the subordinated term loan is approximately \$4.5 million and \$0.3 million, respectively, which, as of September 30, 2024, includes default interest of 5% of approximately \$1.8 million that was assessed by the lender in September 2024. All interest and principal payments to CIBC have been made timely.

On March 13, 2024, we received a notice of default from Oxford, dated March 12, 2024, for the mezzanine loan primarily based on the non-compliance noted above, whereby Oxford exercised certain rights, including, their right to act as attorney-in-fact of GA HoldCo, and appointed an independent manager over the GA8 Properties, thereby removing the Company as the manager and removing the Company’s voting rights and rights to receive any distributions with respect to such properties. The Oxford notice of default also constitutes an event of default under the GA8 Properties subordinated term loan with Oxford and the first priority mortgage loan with CIBC. On May 7, 2024, we received a notice of default and reservation of rights letter from CIBC. There were no actions taken by this notice. See Note 14 for further information regarding the derecognition of the GA8 Properties and related debt.

[Table of Contents](#)

As of September 30, 2024 and December 31, 2023, loans payable associated with GA8 Properties consisted of the following:

	September 30, 2024	December 31, 2023
Loan payable to CIBC Bank, USA in monthly installments of approximately \$850,000 (including interest and principal) variable interest rate (8.7% at September 30, 2024 and 8.86% at December 31, 2023), due in December 2024, and collateralized by Calhoun Health Center, Maple Ridge Health Care Center, Chatsworth Health Care Center, East Lake Arbor, Fairburn Health Care Center, Grandview Health Care Center, Rosemont at Stone Mountain, and Willowood Nursing Center & Rehab (“GA8 Properties”). See Note 14 for additional information.	\$ 89,590,000	\$ 91,000,000
Loan payable to Oxford Finance, LLC in monthly installments of approximately \$280,000 (interest only through maturity), variable interest rate (16.3% at September 30, 2024 and 16.4% at December 31, 2023, respectively) due in March 2025, collateralized in second position by the GA8 Properties. See Note 14 for additional information.	20,000,000	20,000,000
Mezzanine Loan payable to Oxford Finance, LLC in monthly installments of approximately \$180,000 (interest only through maturity), variable interest rate (16.3% at September 30, 2024 and 16.4% at December 31, 2023, respectively) due in December 2026, secured by the equity interests of our wholly-owned subsidiary, Summit Georgia Holdings LLC, the parent holding company for the GA8 Properties. See Note 14 for additional information.	12,750,000	12,750,000
<b>Total loans payable associated with GA8 Properties</b>	<b>\$ 122,340,000</b>	<b>\$ 123,750,000</b>

***HUD-insured loans***

We have six properties with HUD-insured loans from Lument Capital (formerly ORIX Real Estate Capital, LLC) and one property with a HUD-insured loan from Capital One Multifamily Finance, LLC. See table above listing loans payable for further information.

All of the HUD-insured loans are subject to customary representations, warranties and ongoing covenants and agreements with respect to the operation of the facilities, including the provision for certain maintenance and other reserve accounts for property tax, insurance, and capital expenditures, with respect to the facilities all as described in the HUD agreements. These reserves are included in restricted cash in our condensed consolidated balance sheets.

***Master Letter of Credit Agreement***

In September 2023, we entered into a \$1.0 million Master Letter of Credit Agreement with CIBC. As of September 30, 2024, there are no outstanding letters of credit under this agreement.

**5. Equity-Method Investments**

As of September 30, 2024 and December 31, 2023, the balances of our Equity-Method Investments were approximately \$0.4 million and \$2.9 million, respectively, and are as follows:

***Summit Union Life Holdings, LLC***

The SUL JV will exist until an event of dissolution occurs, as defined in the limited liability company agreement of the SUL JV (the “SUL LLC Agreement”).

Under the SUL LLC Agreement, net operating cash flow of the SUL JV is distributed monthly, first to the Operating Partnership and Best Years *pari passu* up to a 9% to 10% annual return, and thereafter to Best Years 75% and the Operating Partnership 25%. All capital proceeds from the sale of the properties held by the SUL JV, a refinancing or another capital event will be paid first to the Operating Partnership and Best Years *pari passu* until each has received an amount equal to its accrued but unpaid 9% to 10% return plus its total contribution, and thereafter to Best Years 75% and the Operating Partnership 25%.

[Table of Contents](#)

For the nine months ended September 30, 2024 and 2023, we invested approximately \$29,000 and \$156,000, respectively, related to capital calls for the SUL JV. In March 2024, the SUL JV sold one property for a gain of \$7.7 million. We recorded our 10% share of the gain of approximately \$0.8 million in income from equity-method investees in the condensed consolidated statements of operations for the nine months ended September 30, 2024 and received approximately \$1.9 million in cash related to the sale. In May 2024, the SUL JV sold one property for a gain of \$1.0 million. We recorded our 10% share of the gain of approximately \$0.1 million in income from equity-method investees in the condensed consolidated statements of operations for the nine months ended September 30, 2024.

As of September 30, 2024 and December 31, 2023, the balance of our equity-method investment related to the SUL JV was approximately \$0.6 million and \$1.8 million, respectively.

***Summit Fantasia Holdings II, LLC***

The Fantasia II JV will exist until an event of dissolution occurs, as defined in the limited liability company agreement of the Fantasia II JV (the “Fantasia II LLC Agreement”). All capital proceeds from the sale of the properties held by the Fantasia II JV, a refinancing or another capital event, will be paid first to the Operating Partnership and Fantasia *pari passu* until each has received an amount equal to its accrued but unpaid 8% return plus its total capital contribution, and thereafter 70% to Fantasia and 30% to the Operating Partnership.

In June 2023, the tenant for the two properties in the Fantasia II JV filed for receivership. The two properties are currently being operated by the receivership estate in conjunction with a third-party manager under an 18 month management agreement. As of September 30, 2024, there has been no termination of the tenant leases and the Fantasia II JV is currently communicating with the receiver and the third-party manager regarding a possible sale of the properties to the third-party manager. The Fantasia II JV has not received any rent payments since May 2023. In September 2023, due to the ongoing issues with the receivership, we determined the fair value of our investment in the Fantasia II JV to be impaired and recorded a \$0.5 million impairment charge. However, due to our intention to fund a capital call in 2024, if needed, we are recording our share of the Fantasia II JV losses.

As of September 30, 2024 and December 31, 2023, due to the losses incurred in the Fantasia II JV, the negative balance of our equity-method investment related to the Fantasia II JV was approximately (\$0.1) million.

***Summit Fantasia Holdings III, LLC***

In May 2024, the Fantasia III JV sold their eight properties for \$60.0 million. We received approximately \$2.1 million in cash from the sale resulting in the winding-up of our equity-method investment and recorded income from the sale of approximately \$0.9 million, which is recorded in income from equity-method investees in the condensed consolidated statements of operations. Due to the sale of the properties, as of May 2, 2024, we no longer have an equity-method investment in the Fantasia III JV.

As of December 31, 2023, the balance of our equity-method investment related to the Fantasia III JV was approximately \$1.2 million.

***Summit Fantasy Pearl Holdings, LLC***

The FPH JV will continue until an event of dissolution occurs, as defined in the limited liability company agreement of the FPH JV (the “FPH LLC Agreement”).

Under the FPH LLC Agreement, net operating cash flow of the FPH JV is distributed monthly, first to the members *pari passu* until each member has received an amount equal to its accrued, but unpaid 9% return, and thereafter 65.25% to Fantasy, 7.5% to Atlantis, 7.25% to Fantasia and 20% to the Operating Partnership. All capital proceeds from the sale of the properties held by the FPH JV, a refinancing or another capital event, will be paid to the members *pari passu* until each has received an amount equal to its accrued but unpaid 9% return plus its total capital contribution, and thereafter 65.25% to Fantasy, 7.5% to Atlantis, 7.25% to Fantasia, and 20% to the Operating Partnership.

[Table of Contents](#)

During 2022 and into 2023, the FPH JV tenants deferred rent and paid reduced rents, and as such, we determined the fair value of our investment in the FPH JV to be impaired and recorded a \$0.2 million impairment charge in 2022. In July 2023, the tenant resumed paying all rents and recorded net income, and therefore, we recorded the income after the losses incurred were reduced to zero, and additionally, recorded distributions, resulting in a negative equity-method investment balance as of September 30, 2024. As of September 30, 2024 and December 31, 2023, the balance of our equity-method investment related to the FPH JV was (\$0.07) million and \$0.

**Distributions from Equity-Method Investments**

As of September 30, 2024 and December 31, 2023, we have distributions receivable, which are included in tenant and other receivables in our condensed consolidated balance sheets, as follows:

	September 30, 2024	December 31, 2023
SUL JV	\$ 209,000	\$ 311,000
Fantasia II JV	30,000	30,000
Fantasia III JV	—	87,000
FPH JV	33,000	64,000
<b>Total</b>	<b>\$ 272,000</b>	<b>\$ 492,000</b>

For the nine months ended September 30, 2024 and 2023, we have received cash distributions, which are included in our cash flows from operating activities in tenant and other receivables, and cash flows from investing activities, as follows:

	Nine months Ended September 30, 2024			Nine months Ended September 30, 2023		
	Total Cash Distributions Received	Cash Flow from Operating Activities	Cash Flow from Investing Activities	Total Cash Distributions Received	Cash Flow from Operating Activities	Cash Flow from Investing Activities
SUL JV	\$ 2,198,000	\$ 904,000	\$ 1,294,000	\$ 408,000	\$ 6,000	\$ 402,000
Fantasia II JV	—	—	—	136,000	—	136,000
Fantasia III JV	2,158,000	916,000	1,242,000	12,000	—	12,000
FPH JV	129,000	—	129,000	—	—	—
<b>Total</b>	<b>\$ 4,485,000</b>	<b>\$ 1,820,000</b>	<b>\$ 2,665,000</b>	<b>\$ 556,000</b>	<b>\$ 6,000</b>	<b>\$ 550,000</b>

**Asset Management Fees**

We serve as the manager of our Equity-Method Investments and provide management services in exchange for fees and reimbursements. As the manager, we are paid an annual asset management fee for managing the properties held by our Equity-Method Investments, as defined in those agreements. For the three months ended September 30, 2024 and 2023, we recorded approximately \$0.05 million and \$0.1 million, respectively, in asset management fees from our Equity-Method Investments. For the nine months ended September 30, 2024 and 2023, we recorded approximately \$0.2 million and \$0.4 million, respectively, in asset management fees from our Equity-Method Investments.

**6. Receivables**

**Tenant and Other Receivables, Net**

Tenant and other receivables, net consists of:

	September 30, 2024	December 31, 2023
Straight-line rent receivables	\$ 1,063,000	\$ 1,396,000
Distribution receivables from Equity-Method Investments (see Note 5)	272,000	492,000
Asset management fees	143,000	327,000
Other receivables	333,000	375,000
<b>Total</b>	<b>\$ 1,811,000</b>	<b>\$ 2,590,000</b>

## 7. Related Party Transactions

### Equity-Method Investments

See Notes 5 and 6 for further discussion of distributions and asset management fees related to our Equity-Method Investments.

## 8. Intangible Lease Assets

Due to the sale of the CA3 Properties in September 2024 (see Note 3) and excluding our eight derecognized real estate properties (see Note 14), there are no intangible lease assets as of September 30, 2024. As of December 31, 2023, intangible lease assets are as follows:

	September 30, 2024	December 31, 2023
In-place leases	\$ —	\$ 12,680,000
Less: accumulated amortization	—	(1,831,000)
In-place leases, net	—	10,849,000
Above-market leases	—	959,000
Less: accumulated amortization	—	(155,000)
Above-market leases, net	—	804,000
Total intangible lease assets, net	\$ —	\$ 11,653,000

For the three months ended September 30, 2024 and 2023, amortization expense for intangible lease assets was approximately \$0.01 million and \$0.2 million, respectively, of which approximately \$0.01 million, respectively, relates to the amortization of above market leases which is included within rental revenues in the accompanying condensed consolidated statements of operations. For the nine months ended September 30, 2024 and 2023, amortization expense for intangible lease assets was approximately \$0.2 million and \$0.7 million, respectively, of which approximately \$0.04 million and \$0.05 million, respectively, relates to the amortization of above-market leases which is included within rental revenues in the accompanying condensed consolidated statements of operations.

## 9. Right of Use (ROU) Asset - Operating

In November 2022, we entered into an operating lease for office space (“Office Lease”) for a period of sixty-six (66) months, with a five-year renewal option. The office space subject to the Office Lease is located in Laguna Hills, California. The Office Lease provides for the abatement of the base rent for the second full calendar month (January 2023) through the seventh full calendar month of the lease term (September 2023). The initial annual base rent is \$204,399 and increases three percent (3%) each year on the anniversary date of the commencement of the Office Lease.

The Office Lease is classified as an operating lease. A “right to use” or “ROU asset” represents the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Office Lease did not provide an explicit rate of interest; therefore we used an estimated incremental borrowing rate of 5% based on a fully collateralized and fully amortizing loan with a maturity date of the same length as the lease that is based on information available at the commencement date in determining the present value of lease payments. The Office Lease does not contain material residual value guarantees or material restrictive covenants.

Supplemental balance sheet information related to the Office Lease are as follows:

Component	Consolidated Balance Sheet Caption	September 30, 2024	December 31, 2023
Right of use asset - operating	Other assets, net	\$ 593,000	\$ 698,000
Lease liability - operating	Accounts payable and accrued liabilities	\$ 750,000	\$ 877,000



[Table of Contents](#)

Lease expense is included within general and administrative expenses in the condensed consolidated statements of operations. For each of the three months ended September 30, 2024 and 2023, we recognized approximately \$0.05 million in lease expense. For each of the nine months ended September 30, 2024 and 2023, we recognized approximately \$0.1 million in lease expense. The lease payments are classified within operating activities in the consolidated statements of cash flows. As of September 30, 2024 and 2023, we paid approximately \$158,000 and \$0, respectively, in lease payments and the weighted average remaining lease term is 3.3 years. See Note 15 for additional information.

Lease payments on the Office Lease for the period from October 1, 2024 to December 31, 2024 and for each of the four following years and thereafter ending December 31 are as follows:

<u>Year</u>	<u>Lease payments</u>
October 1, 2024 to December 31, 2024	\$ 53,000
2025	217,000
2026	224,000
2027	231,000
2028	99,000
Total lease payments	\$ 824,000
Less imputed interest	(74,000)
Total lease liability	\$ 750,000

#### 10. Concentration of Risk

As of September 30, 2024, we owned eight properties in Georgia (see Note 14), one property in California, three properties in Oregon, one property in Texas, one property in Illinois, and one property in Arizona (excluding the 21 properties held by our Equity-Method Investments). Accordingly, there is a geographic concentration of risk subject to economic conditions in certain states.

For the three months ended September 30, 2024, we leased our 13 real estate properties to 11 different tenants under long-term triple net leases, and three of the 11 tenants each represented more than 10% of our rental revenue. For the three months ended September 30, 2023, we leased our 16 real estate properties to 14 different tenants under long-term triple net leases, and three of the 14 tenants each represented more than 10% of our rental revenue.

For the nine months ended September 30, 2024, 13 of our real estate properties were leased to 11 different tenants under long-term triple net leases, and three of the 11 tenants each represented more than 10% of our rental revenue. For the nine months ended September 30, 2023, 16 of our real estate properties were leased to 14 different tenants under long-term triple net leases, and three of the 14 tenants each represented more than 10% of our rental revenue.

As of September 30, 2024, our GA8 Properties are considered to be a significant asset concentration as the aggregate net assets of the GA8 Properties were greater than 20% of our total assets due to cross-default provisions in the leases.

For further information regarding our treatment of the GA8 Properties, see Note 14.

#### 11. Fair Value Measurements of Financial Instruments

Our condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, restricted cash, tenant and other receivables, certain other assets, accounts payable and accrued liabilities, security deposits and loans payable. With the exception of the loans payable discussed below, we consider the carrying values to approximate fair value (categorized within Level 1 of the fair value hierarchy) for such financial instruments because of the short period of time between origination of the instruments and their expected payment.

[Table of Contents](#)

As of September 30, 2024 and December 31, 2023, the fair value of our HUD-insured loans payable was \$37.6 million and \$36.4 million, compared to the principal balance (excluding debt discount) of \$43.0 million and \$43.9 million, respectively. The fair value of loans payable was estimated using lending rates available to us for financial instruments with similar terms and maturities. The fair value of our fixed and variable rate loans payable was estimated by discounting the future cash flows using the current rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities. As the inputs to our valuation estimate are neither observable in nor supported by market activity, our loans payable are classified as Level 3 liability within the fair value hierarchy.

As of September 30, 2024 and December 31, 2023, we believe the carrying amounts of our variable rate loans payable are reasonably estimated at their carrying amounts as there have been minimal changes to the fixed spread portion of interest rates for similar loans observed in the market, and as the variable portion of our interest rates fluctuate with the associated market indices. We believe the fair value of our variable rate mezzanine loan payable, which is currently in default, approximates the carrying amount based on the contractual rights of the mezzanine loan payable holders.

As of September 30, 2024 and December 31, 2023, we do not have any significant financial assets or financial liabilities that are measured at fair value on a recurring basis in our condensed consolidated financial statements.

## **12. Commitments and Contingencies**

We inspect our properties under a Phase I assessment for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist, we are not currently aware of any environmental liability with respect to the properties that would have a material effect on our consolidated financial condition, results of operations and cash flows. Further, we are not aware of any environmental liability or any unasserted claim or assessment with respect to an environmental liability that we believe would require additional disclosure or the recording of a loss contingency.

Our commitments and contingencies include the usual obligations of real estate owners and licensed operators in the normal course of business. In the opinion of management, these matters are not expected to have a material impact on our consolidated financial condition, results of operations and cash flows. We are also subject to contingent losses resulting from litigation against the Company.

### **Legal Proceedings**

#### **HCRE**

The Company is currently engaged in litigation with Healthcare Real Estate Partners, LLC (“HCRE”) regarding certain matters surrounding a September 2015 bankruptcy petition against HCRE and subsequent claims related thereto, as described in greater detail in the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 16, 2024. The Bankruptcy Court entered an Order and Judgment with respect to the amounts set forth below on May 2, 2024. The Company filed a notice of appeal with respect to the \$664,637 fee award, which appeal remains pending. The Company has also asserted counterclaims against HCRE, which are pending in the Delaware District Court, and which are stayed pending a final determination of the matters addressed in the Bankruptcy Court, including the appeal. Based on the assessment by management, as of September 30, 2024, the Company has accrued \$75,000 for the reimbursement of legal fees related to the involuntary petition filing and \$0 for the \$665,000 in attorney’s fees related to the stay violation as we believe that a loss is currently not probable under Accounting Standards Codification 450, “Contingencies.”

#### **Eikanas Dispute**

On June 5, 2023, Kent Eikanas, the Company’s former Chief Executive Officer and Board Member, filed a lawsuit against the Company in the Superior Court of California for, among other things, wrongful termination and breach of contract, and seeking unspecified monetary damages, as described in greater detail in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 16, 2024. On April 8, 2024, Mr. Eikanas amended his Complaint to add additional causes of action and three new defendants – Steven Roush, Board Member; Suzanne Koenig, Board Member; and Elizabeth Pagliarini, Chief Executive Officer and Board Member. Based on the assessment by management, the Company believes that a loss is currently not probable or estimable under ASC 450, “Contingencies”, and as of September 30, 2024, no accrual has been made with regard to the claim.

**Indemnification and Employment Agreements**

We have entered into indemnification agreements with certain of our executive officers and directors which indemnify them, subject to limited exceptions, against all judgments, penalties, fines and amounts paid in settlement and all expenses actually and reasonably incurred by him or her in connection with any proceeding they become involved in by virtue of the status of a person as a present or former director, officer, employee, consultant or agent of the Company.

**Management of our Equity-Method Investments**

As the manager of our Equity-Method Investments, we are responsible for day-to-day management. Additionally, we could be subject to a capital call from our Equity-Method Investments (see Note 5 for capital call activity).

**13. Equity**

**Share-Based Compensation Plans**

Upon the grant of stock options, we determine the exercise price by using our estimated per-share value, which is calculated by aggregating the estimated fair value of our investments in real estate and the estimated fair value of our other assets, subtracting the book value of our liabilities, utilizing a discount for the fact that the shares are not currently traded on a national securities exchange and a lack of a control premium, and divided the total by the number of our common shares outstanding at the time the options were granted.

The fair value of each grant is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions required by the model include the risk-free interest rate, the expected life of the options, the expected stock price volatility over the expected life of the options, and the expected distribution yield. Compensation expense for employee stock options is recognized ratably over the vesting term. The expected life of the options was based on the simplified method as we do not have sufficient historical exercise data. The risk-free interest rate was based on the U.S. Treasury yield curve at the date of grant using the expected life of the options at the date of grant. Volatility was based on historical volatility of the stock prices for a sample of publicly traded companies with risk profiles similar to ours. The valuation model applied in this calculation utilizes highly subjective assumptions that could potentially change over time, including the expected stock price volatility and the expected life of an option.

The following table summarizes our stock options as of September 30, 2024:

	Options	Weighted Average Exercise Price	Weighted Average Remaining Contractual Term	Aggregate Intrinsic Value
Options outstanding at January 1, 2024	1,148,063	\$ 2.16		
Granted	—	\$ —		
Exercised	—			
Cancelled/forfeited	4,167			
Options outstanding at September 30, 2024	<u>1,143,896</u>	<u>\$ 2.16</u>	<u>4.04</u>	<u>\$ —</u>
Options exercisable at September 30, 2024	<u>1,089,535</u>	<u>\$ 2.16</u>	<u>3.82</u>	<u>\$ —</u>

For our outstanding non-vested options as of September 30, 2024, the weighted average grant date fair value per share was \$0.91. As of September 30, 2024, we have unrecognized stock-based compensation expense related to unvested stock options which is expected to be recognized as follows:

<u>Years Ending December 31,</u>		
October 1, 2024 to December 31, 2024	\$	11,000
2025		30,000
2026		8,000
	<u>\$</u>	<u>49,000</u>

[Table of Contents](#)

The stock-based compensation expense reported for each of the three months ended September 30, 2024 and 2023 was approximately \$12,000, and is included in general and administrative expense in the condensed consolidated statements of operations. The stock-based compensation expense reported for the nine months ended September 30, 2024 and 2023 was approximately \$36,000 and \$29,000, respectively, and is included in general and administrative expense in the condensed consolidated statements of operations.

#### 14. Derecognition of GA8 Properties

As noted in Note 4, on March 13, 2024, we received a notice of default from Oxford, dated March 12, 2024, for events of default under the mezzanine loan, whereby Oxford exercised certain rights as the agent, including, their right to act as attorney-in-fact of Summit Georgia Holdings LLC, and appointed an independent manager over the GA8 Properties, thereby removing Summit as the manager and removing our voting rights and rights to receive any distributions with respect to such properties. As such, the independent manager now has control over all activities of the GA8 Properties and Summit no longer has any control or authority over the properties' operations or activities.

As a result of these actions, Summit derecognized the GA8 Properties as of March 12, 2024, the effective date of when the independent manager took control, and accordingly recognized an initial gain of \$17.7 million for the three months ended March 31, 2024. For the three months ended September 30, 2024, we recorded an additional gain of approximately \$6.4 million which is primarily related to the additional accrued interest for the three months ended September 30, 2024, for a total gain of \$27.5 million for the nine months ended September 30, 2024, which is included in gain on derecognition associated with GA8 Properties in our condensed consolidated statements of operations. We initially recorded a contract asset of \$126.1 million as of March 31, 2024, and as of September 30, 2024, the balance is \$130.9 million, which represents the liabilities we expect to be released from upon final resolution with the lender in exchange for the transfer of ownership of the GA8 Properties. The loans payable and accrued interest will remain a liability on our condensed consolidated balance sheets until final resolution with the lender is concluded. As of September 30, 2024 and December 31, 2023, \$122.3 million and \$123.8 million, respectively, is included in loans payable associated with GA8 Properties. As of September 30, 2024, \$8.5 million is included in accrued interest associated with GA8 Properties on our condensed consolidated balance sheets, which includes default interest of approximately \$3.0 million that was assessed by the lender in September 2024, and as of December 31, 2023, \$1.0 million is included in accrued interest associated with GA8 Properties on our condensed consolidated balance sheets.

The following assets and property operating liabilities were derecognized from our condensed consolidated balance sheet upon our loss of control of the GA8 Properties as of March 12, 2024:

	<u>As of March 11, 2024</u>
Real estate properties, net	\$ 97,637,000
Intangible lease assets, net	10,250,000
Cash and other assets	3,096,000
Property operating liabilities (accrued liabilities, deferred financing costs, and security deposits)	(2,620,000)
Derecognized assets and liabilities	<u>\$ 108,363,000</u>

[Table of Contents](#)

The results of operations included in our condensed consolidated statements of operations (including operations from January 1, 2024 through March 11, 2024, the date of derecognition) for the three and nine months ended September 30, 2024 and 2023 are as follows:

Condensed Combined Statements of Operations:	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Total rental revenue	\$ —	\$ 3,663,000	\$ 2,083,000	\$ 10,911,000
Property operating costs	\$ —	\$ 418,000	\$ 75,000	\$ 1,169,000
Depreciation and amortization	\$ —	\$ 1,306,000	\$ 929,000	\$ 3,919,000
Interest expense	\$ 6,434,000	\$ 3,413,000	\$ 10,208,000	\$ 9,806,000

Subsequent to March 11, 2024, we are continuing to accrue interest associated with GA8 Properties and adjusting the contract asset through gain on derecognition of assets with the corresponding changes in loan payable and accrued interest associated with the derecognition of GA8 Properties. For the three months ended September 30, 2024, we recognized approximately \$6.4 million in interest expense, which includes default interest of approximately \$3.0 million that was assessed by the lender in September 2024, and which resulted in a corresponding increase in the gain on derecognition of assets associated with GA8 Properties, and for the nine months ended September 30, 2024, we recognized approximately \$13.2 million in interest expense associated with GA8 Properties, which includes default interest of approximately \$3.0 million that was assessed by the lender in September 2024.

### 15. Subsequent Events

On November 1, 2024, the SUL JV sold four of its properties for \$11.1 million. We received approximately \$1.0 million in proceeds from the sale.

On November 11, 2024, we executed an amendment to the Office Lease to reduce the lease term to April 2026 instead of April 2028. Additionally, the landlord can provide us with a written termination notice at least 30 days prior to the date on which we would be required to surrender the premises, the lease would terminate and we would no longer have any obligations to the landlord.

## **Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.**

The following “Management’s Discussion and Analysis of Financial Condition and Results of Operations” should be read in conjunction with our unaudited condensed consolidated financial statements and notes thereto contained elsewhere in this report. This section contains forward-looking statements, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to numerous risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Forward-looking statements that were true at the time made may ultimately prove to be incorrect or false. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements should be read in light of the risks identified in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (the “SEC”) April 16, 2024.

### **Overview**

As of September 30, 2024, our ownership interests in our 15 real estate properties of senior housing facilities was as follows: 100% ownership of 11 properties (eight of which were derecognized in March 2024 and are included in contract assets (see Note 14 to the accompanying Notes to Condensed Consolidated Financial Statements)), and a 95.3% interest in four properties in a consolidated joint venture, Cornerstone Healthcare Partners LLC. We also have three unconsolidated equity-method investments (collectively, our “Equity-Method Investments”) with interests ranging from 10% - 20% that hold an aggregate of 21 properties. As used in this report, the “Company,” “we,” “us” and “our” refer to Summit Healthcare REIT, Inc. and its consolidated subsidiaries, except where the context otherwise requires.

Our revenues are comprised largely of tenant rental income from our real estate properties, including rents reported on a straight-line basis over the initial term of each tenant lease, resident fees and services and asset management fees resulting from our Equity-Method Investments. We also receive cash distributions from our Equity-Method Investments, which are included in net cash provided by operating activities and net cash provided by investing activities in our condensed consolidated statements of cash flows. Our growth depends, in part, on our ability to continue to raise joint venture equity or other equity, acquire new healthcare properties at attractive prices, negotiate long-term tenant leases with sustainable rental rate escalation terms and control our expenses. Our operations are impacted by property-specific, market-specific, general economic, regulatory and other conditions.

We believe that continued investing in senior housing facilities is accretive to earnings and stockholder value. Senior housing facilities include independent living facilities (“IL”), skilled nursing facilities (“SNF”), assisted living facilities (“AL”), memory care facilities (“MC”) and continuing care retirement communities (“CCRC”). Each of these types of facilities focuses on different segments of the senior population. Our current properties are SNF, AL, and MC facilities.

### **Current Market and Economic Conditions**

The U.S. economy is experiencing a mixed but stable environment currently. The Federal Reserve has started cutting interest rates in response to cooling inflation and a softer job market. More rate cuts are expected and economic conditions are moderating, but risks remain. Geopolitical tensions and other headwinds could impact inflation and growth moving forward.

More specifically, the seniors housing and care real estate market continues to be significantly impacted. Higher interest rates and inflation have increased operational costs for seniors housing facilities, particularly as providers face mounting staffing shortages, wage pressures, and new regulations that mandate minimum staffing levels.

The prolonged period of high and persistent inflation has caused an increase in our expenses. These economic conditions have had a material impact on our business, cash flow and results of operations. They could also impact our ability to find suitable acquisitions, sell properties, and raise equity and debt capital.

### **Summit Portfolio Properties**

At September 30, 2024, our portfolio consisted of 15 real estate properties as noted above in the Overview section of this Item 2, 13 of which were 100% triple-net leased to the tenants of the related facilities. The other two properties are each 100% leased to an affiliated subsidiary for which we operate directly and earn resident fees and services revenue.

[Table of Contents](#)

The following table provides summary information (excluding the 21 properties held by our unconsolidated Equity-Method Investments, but including our 8 real estate properties derecognized on March 12, 2024 (see Note 14 to the accompanying Notes to Condensed Consolidated Financial Statements)) regarding these properties as of September 30, 2024:

	Properties	Beds	Square Footage	Purchase Price
SNF	12	1,163	356,836	\$ 161,740,000
AL or AL/MC	3	221	136,765	25,525,000
<b>Total Real Estate Properties</b>	<b>15</b>	<b>1,384</b>	<b>493,601</b>	<b>\$ 187,265,000</b>

Property	Location	Date Purchased	Type	Beds	2024 Lease Revenue <sup>(1)</sup>
Sheridan Care Center	Sheridan, OR	August 3, 2012	SNF	51	\$ 425,000
Fernhill Care Center	Portland, OR	August 3, 2012	SNF	63	454,000
Friendship Haven Healthcare and Rehabilitation Center	Galveston County TX	September 14, 2012	SNF	150	1,059,000
Pacific Health and Rehabilitation Center	Tigard, OR	December 24, 2012	SNF	73	832,000
Brookstone of Aledo	Aledo, IL	July 2, 2013	AL	66	573,000
Sundial Assisted Living <sup>(2)</sup>	Redding, CA	December 18, 2013	AL	65	—
Pennington Gardens <sup>(2)</sup>	Chandler, AZ	July 17, 2017	AL/MC	90	—
Calhoun Health Center <sup>(3)</sup>	Calhoun, GA	December 30, 2021	SNF	100	74,000
Maple Ridge Health Care Center <sup>(3)</sup>	Cartersville, GA	December 30, 2021	SNF	74	292,000
Chatsworth Health Care Center <sup>(3)</sup>	Chatsworth, GA	December 30, 2021	SNF	120	534,000
East Lake Arbor <sup>(3)</sup>	Decatur, GA	December 30, 2021	SNF	103	139,000
Fairburn Health Care Center <sup>(3)</sup>	Fairburn, GA	December 30, 2021	SNF	120	223,000
Grandview Health Care Center <sup>(3)</sup>	Jasper, GA	December 30, 2021	SNF	60	164,000
Rosemont at Stone Mountain <sup>(3)</sup>	Stone Mountain, GA	December 30, 2021	SNF	149	422,000
Willowood Nursing Center & Rehab <sup>(3)</sup>	Flowery Branch, GA	December 30, 2021	SNF	100	159,000
<b>Total</b>				<b>1,384</b>	

(1) Represents year-to-date rental revenue based on in-place leases, including straight-line rent, through September 30, 2024 and excluding \$0.8 million in tenant reimbursement revenue and \$0.04 million in above-market lease amortization.

(2) Lease revenue due under Pennington Gardens and Sundial (collectively, the “Operated Properties”) intercompany leases are eliminated in consolidation and revenue is reflected in resident fees and services in the accompanying condensed consolidated statements of operations for the Operated Properties.

(3) Included as contract assets as of September 30, 2024 and total rental revenue is through March 12, 2024, the date of derecognition.

## **GA8 Properties**

On March 13, 2024, we received a notice of default from Oxford Finance, LLC (“Oxford”), dated March 12, 2024, for events of default under the mezzanine loan for Summit Georgia Holdings LLC, the sole member of the GA8 Properties, whereby Oxford exercised certain rights as the agent, including, their right to act as attorney-in-fact of Summit Georgia Holdings LLC, and appointed an independent manager over the GA8 Properties, thereby removing Summit as the manager and removing the voting rights and rights to receive any distributions with respect to such properties. As such, the independent manager now has control over all activities of the GA8 Properties and Summit no longer has any control or authority over the properties’ operations or activities. As a result of these actions, Summit derecognized the operating assets and liabilities associated with the GA8 Properties as of March 12, 2024.

As a result of these actions, Summit recorded, as of September 30, 2024, a contract asset of approximately \$130.9 million, which represents the liabilities we expect to be released from upon final resolution with the lender, and is included in the accompanying condensed consolidated balance sheet in contract assets associated with GA8 Properties. The loans payable of \$122.3 million is included in the accompanying condensed consolidated balance sheet as of September 30, 2024 in loans payable associated with GA8 Properties, and accrued interest of approximately \$8.6 million related to GA8 Properties is included in the accompanying condensed consolidated balance sheet as of September 30, 2024 in accrued interest associated with GA8 Properties.

## **Summit Equity-Method Investment Portfolio Properties**

We continue to believe that raising institutional capital to make acquisitions will be accretive to shareholder value. Our primary source of capital since 2015 has been institutional funds raised through a joint venture structure and accounted for as equity-method investments. We still believe this is a prudent strategy for growth; however, in the future, we may raise additional equity capital through alternative methods if warranted by market conditions.

### ***Summit Union Life Holdings, LLC***

In April 2015, through our operating partnership (“Operating Partnership”), we formed Summit Union Life Holdings, LLC (“SUL JV”) with Best Years, LLC (“Best Years”), an unrelated entity and a U.S.-based affiliate of Union Life Insurance Co, Ltd. (a Chinese corporation), and entered into a limited liability company with Best Years with respect to the SUL JV (the “SUL LLC Agreement”). We have a 10% interest in the SUL JV which owns 13 properties. The SUL JV is not consolidated in our condensed consolidated financial statements and is accounted for under the equity-method in our condensed consolidated financial statements.

In March 2024, the SUL JV sold one of the properties for a total gain of approximately \$7.8 million. We received approximately \$1.9 million in cash in April 2024 from the capital proceeds of the sale (of which approximately \$0.1 million was our 10% accrued but unpaid return plus our total contribution and approximately \$1.8 million was 25% of the remaining proceeds as due to us per the SUL LLC Agreement). In May 2024, the SUL JV sold one of the properties for a total gain of approximately \$0.9 million and for the nine months ended September 30, 2024, we recorded our 10% of the gain on the sales of approximately \$0.1 million. As of September 30, 2024, the balance of our equity-method investment related to the SUL JV was approximately \$0.6 million.

### ***Equity-Method Partner – Fantasia Investment III LLC***

In 2016 and 2017, through our Operating Partnership, we entered into two separate limited liability company agreements (collectively, the “Fantasia Agreements”) with Fantasia Investment III LLC (“Fantasia”), an unrelated entity and a U.S.-based affiliate of Fantasia Holdings Group Co., Limited (a Chinese corporation listed on the Stock Exchange of Hong Kong (HKEX)), and formed two separate companies, Summit Fantasia Holdings II, LLC (“Fantasia II JV”) of which we own a 20% interest in two skilled nursing facilities located in Rhode Island, and through May 1, 2024, Summit Fantasia Holdings III, LLC (“Fantasia III JV”), for which we owned a 10% interest in eight skilled nursing facilities located in Connecticut (collectively, the “Fantasia JVs”).

The Fantasia JVs are not consolidated in our condensed consolidated financial statements and are accounted for under the equity-method in our condensed consolidated financial statements.

In 2023, the tenants of the two properties in the Fantasia II JV filed for a receivership with the state of Rhode Island and in September 2023, due to the ongoing receivership issues, we determined the fair value of our equity-method investment in the Fantasia II JV to be impaired and wrote off our equity-method balance. However, due to a change in our intention to fund a capital call, if needed, we have recorded additional losses and as of September 30, 2024, the balance of our equity-method investment related to the Fantasia II JV was approximately (\$0.1) million.



[Table of Contents](#)

In May 2024, the Fantasia III JV sold their eight properties for approximately \$60.0 million. We received approximately \$2.1 million in cash from the sale resulting in the winding-up of our equity-method investment and as such, as of May 2, 2024, we no longer have an equity-method interest in the Fantasia III JV.

***Summit Fantasy Pearl Holdings, LLC***

In October 2017, through our Operating Partnership, we entered into a limited liability company agreement (the “FPH LLC Agreement”) with Fantasia, Atlantis Senior Living 9, LLC, a Delaware limited liability company (“Atlantis”), and Fantasy Pearl LLC, a Delaware limited liability company (“Fantasy”), and formed Summit Fantasy Pearl Holdings, LLC (the “FPH JV”). The FPH JV is not consolidated in our condensed consolidated financial statements and is accounted for under the equity-method in our condensed consolidated financial statements. Due to the tenant resuming regular rent payments in July 2023, we have resumed recording the equity-method interest income and distributions as of April 2024. As of September 30, 2024, the balance of our equity-method investment related to the FPH JV was approximately (\$0.07) million.

***Distributions from Equity-Method Investments***

For the nine months ended September 30, 2024 and 2023, we recorded distributions and cash received for distributions from our Equity-Method Investments as follows:

	<b>Nine Months Ended September 30,</b>	
	<b>2024</b>	<b>2023</b>
<b>Distributions</b>	<b>\$ 4,265,000</b>	<b>\$ 588,000</b>
<b>Cash received for distributions</b>	<b>\$ 4,485,000</b>	<b>\$ 555,000</b>

**Critical Accounting Policies**

There have been no material changes to our critical accounting policies as previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC on April 16, 2024.

**Results of Operations**

Our results of operations are described below:

**Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023**

	Three Months Ended September 30,		\$ Change
	2024	2023	
Total rental revenues (excludes security deposits below)	\$ 1,718,000	\$ 4,132,000	\$ (2,414,000)
Property operating costs	(210,000)	(917,000)	707,000
Resident fees and services income	1,788,000	2,084,000	(296,000)
Resident costs	(1,601,000)	(2,095,000)	494,000
Net operating income <sup>(1)</sup>	1,695,000	3,204,000	(1,509,000)
Asset management fees	55,000	129,000	(74,000)
Security deposits from terminated leases	—	420,000	(420,000)
General and administrative	(986,000)	(1,403,000)	417,000
Depreciation and amortization	(408,000)	(2,066,000)	1,658,000
Impairment of real estate properties	—	(11,387,000)	11,387,000
Gain on derecognition of assets associated with GA8 Properties	6,434,000	—	6,434,000
Gain on sale of real estate properties	11,151,000	—	11,151,000
Loss from equity-method investees	(69,000)	(1,671,000)	1,602,000
Gain on consolidation of interest in unconsolidated equity-method investment	—	1,066,000	(1,066,000)
Other income	148,000	103,000	45,000
Interest expense (including interest expense associated with GA8 Properties)	(7,178,000)	(4,542,000)	(2,636,000)
Net income (loss)	10,842,000	(16,147,000)	26,989,000
Noncontrolling interests' share in (income) loss	(36,000)	38,000	(74,000)
Net income (loss) applicable to common stockholders	\$ 10,806,000	\$ (16,109,000)	\$ 26,915,000

(1) Net operating income (“NOI”) is a non-GAAP supplemental measure used to evaluate the operating performance of real estate properties. We define NOI as total rental revenues, resident fees and services revenue less property operating and resident costs. NOI excludes asset management fees, security deposits from terminated leases, general and administrative expense, depreciation and amortization, income (loss) from equity-method investees, impairment and gains of real estate properties, other income, and interest expense. We believe NOI provides investors relevant and useful information because it measures the operating performance of the REIT’s real estate at the property level on an unleveraged basis. We use NOI to make decisions about resource allocations and to assess and compare property-level performance. We believe that net income (loss) is the most directly comparable GAAP measure to NOI. NOI should not be viewed as an alternative measure of operating performance to net income (loss) as defined by GAAP since it does not reflect the aforementioned excluded items. Additionally, NOI as we define it may not be comparable to NOI as defined by other REITs or companies, as they may use different methodologies for calculating NOI.

Total rental revenues for our properties includes rental revenues and tenant reimbursements for property taxes and insurance. Resident fees and services income are generated from the Operated Properties. Property operating costs include insurance and property taxes, and resident costs are related to the Operated Properties. Net operating income decreased approximately \$1.5 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 primarily due to the derecognition of the GA8 Properties as of March 12, 2024, which resulted in a decrease in total rental revenues and property operating costs (which includes no straight-line rent for the three months ended September 30, 2024) of approximately \$1.7 million and \$0.1 million from the sale of the CA3 Properties in September 2024, offset by an increase of \$0.5 million due to the changes in certain leases for our JV properties in September 2023 and by an increase in net operating income of approximately \$0.2 million for the Operated Properties.

The decrease in general and administrative of \$0.4 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 is primarily due to a decrease in payroll and legal of approximately \$0.3 million and \$0.2 million, respectively, offset by the cancellation of a software project of \$0.1 million.

The decrease in depreciation and amortization of \$1.7 million for the three months ended September 30, 2024 compared to the three months ended September 30, 2023 is primarily due to the derecognition of the GA8 Properties and no longer recording depreciation and amortization expense.

[Table of Contents](#)

The impairment of real estate properties for the three months ended September 30, 2023 of \$11.4 million is related to the GA8 properties. See Note 14 to the accompanying Notes to Condensed Consolidated Financial Statements for further information.

The approximately \$6.4 million gain on derecognition of assets associated with GA8 Properties resulted from the derecognition of the GA8 Properties in March 2024, related specifically to the additional interest expense accrued for the three months ended September 30, 2024. See Note 14 in the accompanying Notes to the Condensed Consolidated Financial Statements.

The gain on sale of real estate properties for the three months ended September 30, 2024 of \$11.2 million is related to the sale of CA3 properties. See Note 3 to the accompanying Notes to Condensed Consolidated Financial Statements for further information.

The decrease in loss from equity-method investees of approximately \$1.6 million compared to the three months ended September 30, 2023 is mainly due to the impairment loss and write off of the equity-method investment of \$1.2 million related to the Fantasia II JV, our share of the impairment in one property in the SUL JV of \$0.1 million, and loss from the Fantasia III JV for \$0.4 million in the three months ended September 30, 2023 and no impairment or write-offs in the three months ended September 30, 2024.

The change in gain on consolidation of interest in unconsolidated equity-method investment of approximately \$1.1 million is due to the consolidation of a variable interest entity (Fantasia I JV) in July 2023 and the related gain and then the subsequent sale of the real estate in September 2023.

***Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023***

	Nine Months Ended September 30,		\$ Change
	2024	2023	
Total rental revenues (excludes security deposits below)	\$ 7,648,000	\$ 14,878,000	\$ (7,230,000)
Property operating costs	(1,164,000)	(2,469,000)	1,305,000
Resident fees and services revenue	5,217,000	5,086,000	131,000
Resident costs	(4,458,000)	(4,362,000)	(96,000)
Net operating income <sup>(1)</sup>	7,243,000	13,133,000	(5,890,000)
Asset management fees	219,000	423,000	(204,000)
Security deposits from terminated leases	—	420,000	(420,000)
General and administrative	(3,360,000)	(3,598,000)	238,000
Depreciation and amortization	(2,358,000)	(5,685,000)	3,327,000
Impairment of real estate properties	—	(11,387,000)	11,387,000
Gain on derecognition of assets associated with GA8 Properties	27,455,000	—	27,455,000
Gain on sale of real estate properties	11,151,000	—	11,151,000
Income (loss) from equity-method investees	1,797,000	(1,429,000)	3,226,000
Gain on consolidation of interest in unconsolidated equity-method investment	—	1,066,000	(1,066,000)
Other income	349,000	299,000	50,000
Interest expense (including interest expense associated with GA8 Properties)	(15,850,000)	(13,010,000)	(2,840,000)
Net income (loss)	26,646,000	(19,768,000)	46,414,000
Noncontrolling interests' share in (income) loss	(83,000)	2,000	(85,000)
Net income (loss) applicable to common stockholders	<u>\$ 26,563,000</u>	<u>\$ (19,766,000)</u>	<u>\$ 46,329,000</u>

Total rental revenues for our properties includes rental revenues and tenant reimbursements for property taxes and insurance. Resident fees and services income are generated from the Operated Properties. Property operating costs include insurance, and property taxes, and resident costs are related to the Operated Properties. Net operating income decreased approximately \$5.9 million for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 primarily due to the derecognition of the GA8 Properties as of March 12, 2024, which resulted in a decrease in total rental revenues and property operating costs (which includes no straight-line rent for the three months ended September 30, 2024) of approximately \$5.9 million and \$0.1 million from the sale of the CA3 Properties in September 2024, offset by an increase of \$0.1 million due to the changes in certain leases for our JV properties in September 2023.

[Table of Contents](#)

The decrease in general and administrative of \$0.2 million for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 is primarily due to a decrease in payroll of approximately \$0.4 million offset by the cancellation of a software project and other expenses of \$0.2 million.

The decrease in depreciation and amortization of \$3.3 million for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023 is primarily due to the derecognition of the GA8 Properties in March 2024 and no longer recording depreciation and amortization expense.

The impairment of real estate properties for the nine months ended September 30, 2023 of \$11.4 million is related to the GA8 properties. See Note 14 to the accompanying Notes to Condensed Consolidated Financial Statements for further information.

The approximately \$27.5 million gain on derecognition of assets associated with GA8 Properties resulted from the derecognition of the GA8 Properties in March 2024, specifically related to the additional interest expense of approximately \$8.5 million accrued for the nine months ended September 30, 2024 and the original gain of \$17.7 million recorded in March 2024. See Note 14 in the accompanying Notes to the Condensed Consolidated Financial Statements.

The gain on sale of real estate properties for the nine months ended September 30, 2024 of \$11.2 million is related to the sale of CA3 properties. See Note 3 to the accompanying Notes to Condensed Consolidated Financial Statements for further information.

The change from loss to income from equity-method investees of approximately \$3.2 million compared to the nine months ended September 30, 2023 is mainly due to income for the nine months ended September 30, 2024 of approximately \$1.6 million (\$0.8 million equity-method income recorded from the sale of the properties in the SUL JV and \$0.8 million equity-method income recorded from the sale of properties in the Fantasia III JV in May 2024) and losses from equity-method investees for the nine months ended September 30, 2023 related to the impairment loss and write off of the equity-method investment of approximately \$1.2 million related to the Fantasia II JV, our share of the impairment in one property in the SUL JV of \$0.1 million.

The change in gain on consolidation of interest in unconsolidated equity-method investment of approximately \$1.1 million is due to the consolidation of a variable interest entity (Fantasia I JV) in July 2023 and the related gain and then the subsequent sale of the real estate in September 2023.

#### **Liquidity and Capital Resources**

As of September 30, 2024, we had approximately \$24.2 million in cash and cash equivalents on hand. Based on current conditions, we believe that we have sufficient capital resources to sustain operations.

Going forward, we expect our primary sources of cash to be rental revenues and equity-method investment distributions. In addition, we may increase cash through the sale of additional properties, which may result in the derecognition of properties we already own, or borrowing against currently-owned properties. For the foreseeable future, we expect our primary uses of cash to be for funding future acquisitions, investments in joint ventures, operating expenses, interest expense on outstanding indebtedness and the repayment of principal on loans payable. We may also incur expenditures for renovations of our existing properties, making our facilities more appealing in their market.

Seven of our loans payable obligations are long-term, fixed rate U.S. Department of Housing and Urban Development (“HUD”)—insured loans that mature between 2039 and 2055. The other loan payable obligations are short-term loans that mature in December 2024 through December 2026 with variable interest rates. See Notes 4 and 14 to the accompanying Notes to Condensed Consolidated Financial Statements for further information regarding management’s plan of action to address the maturity of these loans payable.

Additionally, the current interest rate environment has had a negative effect on our results of operations, which could result in foreclosure or other action (see Notes 4 and 14 to the accompanying Notes to Condensed Consolidated Financial Statements); however, we are currently working with the GA8 Properties’ lenders and expect the liabilities associated with the GA8 Properties to be released upon final resolution with the lender in exchange for the transfer of ownership of the GA8 Properties. Our liquidity will increase if cash from operations exceeds expenses, we receive net proceeds from the sale of whole or partial interest in a property or properties, or refinancing results in excess loan proceeds. Our liquidity will decrease as proceeds are expended in connection with our acquisitions and operation of properties. In regard to our Operated Properties, our intent is to stabilize the operations of the facilities and market them for sale due to the significantly reduced willingness of AL manager/operators to execute long-term triple-net leases.

### ***Credit Facilities and Loan Agreements***

As of September 30, 2024, we had debt obligations of approximately \$43.0 million, excluding the loans payable associated with the GA8 Properties. The outstanding balance by lender, excluding loans payable associated with the GA8 Properties, is as follows (see Notes 4 and 14 to the accompanying Notes to Condensed Consolidated Financial Statements for further information regarding our GA8 Properties):

- Capital One Multifamily Finance, LLC (HUD-insured) – approximately \$9.8 million maturing September 2053
- Lument Capital (formerly ORIX Real Estate Capital, LLC) (HUD-insured) – approximately \$33.2 million maturing from September 2039 through April 2055
- CIBC Bank, USA-Master Letter of Credit Agreement for \$1.0 million (none outstanding)

### ***Distributions***

We made no stockholder distributions during the nine months ended September 30, 2024.

### **Funds from Operations (“FFO”)**

FFO is a non-GAAP supplemental financial measure that is widely recognized as a measure of REIT operating performance. We compute FFO in accordance with the definition outlined by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO as net income (loss), computed in accordance with GAAP, excluding gains or losses from sales of property, plus depreciation and amortization and after adjustments for unconsolidated partnerships and joint ventures.

Our FFO may not be comparable to FFO reported by other REITs that do not define the term in accordance with the current NAREIT definition or that interpret the current NAREIT definition differently than we do. We believe that FFO is helpful to investors and our management as a measure of operating performance because it excludes real estate depreciation and amortization, gains and losses from property dispositions, impairments and extraordinary items, and as a result, when compared period to period, reflects the impact on operations from trends in occupancy rates, rental rates, operating costs, development activities, general and administrative expenses, and interest costs, which is not immediately apparent from net income. Historical cost accounting for real estate assets in accordance with GAAP implicitly assumes that the value of real estate diminishes predictably over time. Since real estate values have historically risen or fallen with market conditions, many industry investors and analysts have considered the presentation of operating results for real estate companies that use historical cost accounting alone to be insufficient. As a result, our management believes that the use of FFO, together with the required GAAP presentations, provide a more complete understanding of our performance. Factors that impact FFO include start-up costs, fixed costs, delays in buying assets, lower yields on cash held in accounts pending investment, income from portfolio properties and other portfolio assets, interest rates on acquisition financing and operating expenses. FFO should not be considered as an alternative to net income (loss), as an indication of our performance, nor is it indicative of funds available to fund our cash needs, including our ability to make distributions.

[Table of Contents](#)

The following is the reconciliation from net income (loss) applicable to common stockholders, the most direct comparable financial measure calculated and presented with GAAP, to FFO for the three and nine months ended September 30, 2024 and 2023:

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Net income (loss) applicable to common stockholders (GAAP)	\$ 10,806,000	\$ (16,109,000)	\$ 26,563,000	\$ (19,766,000)
Adjustments:				
Depreciation and amortization	386,000	2,049,000	2,300,000	5,644,000
Depreciation and amortization related to non-controlling interests	(8,000)	(23,000)	(26,000)	(43,000)
Depreciation related to Equity-Method Investments	105,000	183,000	365,000	549,000
Impairment on real estate property in Equity-Method Investments (included in loss from Equity-Method Investments)	—	423,000	—	423,000
Impairment on real estate properties	—	11,387,000	—	11,387,000
Gain on consolidation of interest in unconsolidated equity-method investment	—	(1,066,000)	—	(1,066,000)
Gain on sale of properties in Equity-Method Investments (included in income from Equity-Method Investments)	—	—	(1,614,000)	—
Gain on sale of real estate properties	(11,151,000)	—	(11,151,000)	—
Gain on derecognition of assets associated with GA8 Properties	(6,434,000)	—	(27,455,000)	—
Funds used in operations (FFO) applicable to common stockholders	\$ (6,296,000)	\$ (3,156,000)	(11,018,000)	\$ (2,872,000)
Weighted-average number of common shares outstanding - basic and diluted	23,027,978	23,027,978	23,027,978	23,027,978
FFO per weighted average common shares - basic and diluted	\$ (0.27)	\$ (0.14)	\$ (0.48)	\$ (0.12)

**Subsequent Events**

See Note 15 to the accompanying Notes to Condensed Consolidated Financial Statements.

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

Not applicable.

**Item 4. Controls and Procedures.**

**Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our senior management, including our Chief Executive Officer (Principal Executive Officer) and our Chief Financial Officer (Principal Financial Officer), to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) evaluated the effectiveness of our disclosure controls and procedures and concluded that the disclosure controls and procedures were not effective as of the end of the period covered by this report because of our continued remediation of the material weakness identified in our Annual Report on Form 10-K, as discussed in greater detail below. We believe the disclosure deficiencies with respect to the notice of default were primarily due to the unusual nature of such events and the time needed to assess the implications of the notice for the Company.

We have taken, and continue to take, steps to remediate the control deficiencies contributing to the disclosure deficiencies identified above. Management has reviewed our processes and controls related to our disclosures surrounding events of defaults, and have educated control owners concerning the principles and requirements around controls related to these events. Management is exploring the implementation of new processes to help mitigate the risk that the relevant controls do not operate effectively.

### **Changes in Internal Controls over Financial Reporting**

As disclosed in our Annual Report on Form 10-K, based on their evaluation, our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer) had concluded that our internal control over financial reporting was not effective as of December 31, 2023. As part of the fiscal year 2023 audit, management identified a material weakness. Specifically, the Company failed to design, maintain and monitor certain financial reporting controls specific to significant and unusual transactions, as a result of insufficient technical accounting resources at the Company. Consequently, the Company failed to properly analyze and assess certain events for technical accounting implications in a timely fashion.

We have taken, and continue to take, steps to remediate the control deficiencies contributing to the material weakness described above. These remediation actions have included hiring consultants to assist the Company in the design, maintenance and monitoring of certain financial reporting controls that will prevent such deficiencies in the future, as well as to provide technical accounting resources when the Company may not have such resources within the accounting function at the Company, especially when complex transactions are entered into. Management will report regularly to our Audit Committee on the progress and results of our remediation plan, and we may take additional measures to address these control deficiencies, or we may modify certain of the remediation measures described above.

Other than as described above, there have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II — OTHER INFORMATION**

### **Item 1. Legal Proceedings.**

See Note 12 to the accompanying Notes to Condensed Consolidated Financial Statements for a summary of our material legal proceedings.

### **Item 1A. Risk Factors.**

There have been no material changes to the Risk Factors described in Part I, Item 1A, Risk Factors, in our Annual Report on Form 10-K for the year ended December 31, 2023.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

- (a) We did not sell any equity securities that were not registered under the Securities Act of 1933, as amended, during the periods covered by this Form 10-Q.
- (b) Not applicable.
- (c) During the nine months ended September 30, 2024, we have not redeemed any of our equity securities.

### **Item 3. Defaults Upon Senior Securities.**

See Notes 4 and 14 to the accompanying Notes to Condensed Consolidated Financial Statements with respect to the status of our loans payable.

### **Item 4. Mine Safety Disclosures.**

None.

### **Item 5. Other Information.**

None of our directors or officers adopted, modified, or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the nine months ended September 30, 2024, as such terms are defined under Item 408(a) of Regulation S - K.

The Company has determined to defer holding an Annual Meeting of Stockholders until further notice. The Company will make further announcements when it has determined a new date for its next Annual Meeting of Stockholders.

[Table of Contents](#)

**Item 6. Exhibits.**

<u>Ex.</u>	<u>Description</u>
10.1	<a href="#">Purchase and Sale Agreement, dated February 1, 2024, by and between Summit Yucaipa, LLC, Summit Mentone LLC, and Summit Creekside, LLC, and Rockwell Healthcare Propco RE, LLC, as amended on April 1, 2024, May 1, 2024, May 30, 2024 and August 27, 2024 (incorporated by reference to the Current Report on Form 8-K filed on September 11, 2024).</a>
31.1	<a href="#">Certification of Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2	<a href="#">Certification of Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32	<a href="#">Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
101.1	The following information from the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2024, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statements of Cash Flows.
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)



**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this quarterly report to be signed on its behalf by the undersigned, thereunto duly authorized.

SUMMIT HEALTHCARE REIT, INC.

Date: November 13, 2024

/s/ Elizabeth A. Pagliarini  
Elizabeth A. Pagliarini  
*Chief Executive Officer*  
*(Principal Executive Officer)*

Date: November 13, 2024

/s/ Sharyn I. Grant  
Sharyn I. Grant  
*Chief Financial Officer*  
*(Principal Financial Officer)*

**CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER**

I, Elizabeth A. Pagliarini, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Summit Healthcare REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2024

/s/ Elizabeth A. Pagliarini  
Elizabeth A. Pagliarini  
Chief Executive Officer  
(Principal Executive Officer)

---

**CERTIFICATIONS OF PRINCIPAL FINANCIAL OFFICER**

I, Sharyn I. Grant, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Summit Healthcare REIT, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2024

Sharyn I. Grant  
\_\_\_\_\_  
Sharyn I. Grant  
*Chief Financial Officer*  
*(Principal Financial Officer)*

---

CERTIFICATIONS PURSUANT TO  
18 U.S.C. §1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Elizabeth A. Pagliarini, the Company's Chief Executive Officer, and Sharyn I. Grant, the Company's Chief Financial Officer, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge, the Quarterly Report of Summit Healthcare REIT, Inc. on Form 10-Q for the period ended September 30, 2024 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Form 10-Q fairly presents in all material respects the financial condition and results of operations of Summit Healthcare REIT, Inc.

Date: November 13, 2024

/s/ Elizabeth A. Pagliarini  
Elizabeth A. Pagliarini  
*Chief Executive Officer*  
*(Principal Executive Officer)*

Date: November 13, 2024

/s/ Sharyn I. Grant  
Sharyn I. Grant  
*Chief Financial Officer*  
*(Principal Financial Officer)*

---